Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122525 | 0.88 | NPC1 (0.45) | NPC1VCPHRH3 | |
| SCHEMBL21933627 | 0.76 | NPC1 (0.41) | NPC1VCP | |
| SCHEMBL24233184 | 0.74 | NPC1 (0.46) | NPC1VCPHRH3 | |
| SCHEMBL27013338 | 0.74 | NPC1 (0.50) | NPC1VCPHRH3 | |
| SCHEMBL18389833 | 0.74 | NPC1 (0.58) | NPC1VCPHRH3 | |
| SCHEMBL21673532 | 0.73 | NPC1 (0.34) | NPC1VCP | |
| SCHEMBL18270441 | 0.73 | — | — | |
| SCHEMBL22520618 | 0.72 | NPC1 (0.56) | NPC1VCPHRH3 | |
| SCHEMBL26949128 | 0.72 | NPC1 (0.47) | NPC1VCPHRH3 | |
| SCHEMBL29343603 | 0.71 | HRH3 (0.32) | NPC1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | NPC1 4506/4885VCP 2794/4885HRH3 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.